Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5463189 | 0.91 | TACR2 (0.41) | PDE10AABCB1GRIN2BSLC6A2SLC6A4 | |
| SCHEMBL5462674 | 0.91 | PDE10A (0.41) | PDE10AABCB1GRIN2BSLC6A2SLC6A4 | |
| SCHEMBL5470366 | 0.87 | CCR1 (0.47) | ABCB1GRIN2BCCR1 | |
| SCHEMBL5462556 | 0.84 | ADRA1D (0.39) | GRIN2BADRA1DADRA1AADRA1BKCNJ1 | |
| SCHEMBL5702162 | 0.83 | PDE10A (0.40) | PDE10AABCB1SLC6A4KCNH2 | |
| SCHEMBL5463199 | 0.82 | GRIN2B (0.52) | PDE10AABCB1GRIN2B | |
| SCHEMBL5457356 | 0.82 | KCNH2 (0.54) | ABCB1GRIN2BKCNH2 | |
| SCHEMBL5463829 | 0.81 | GRIN2B (0.44) | GRIN2BKCNH2 | |
| SCHEMBL5461404 | 0.80 | KCNH2 (0.44) | ABCB1ADRA1DADRA1AADRA1BCCR1 | |
| SCHEMBL5457368 | 0.80 | ABCB1 (0.44) | PDE10AABCB1GRIN2BCCR1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | PDE10A 3489/4885ABCB1 803/4885GRIN2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.